title: Role of dopamine D1 and D2 receptors in the nucleus accumbens shell on the acquisition and expression of fructose-conditioned flavor-flavor preferences in rats.
abstract: Systemic administration of dopamine D1 (SCH23390) and less so D2 (raclopride) receptor antagonists significantly reduce acquisition and expression of fructose-conditioned flavor preferences (CFP). Because dopamine in the nucleus accumbens shell (NAcS) is implicated in food reward, the present study examined whether NAcS D1 or D2 antagonists altered acquisition and/or expression of fructose-CFP. In Experiment 1, food-restricted rats with bilateral NAcS cannulae were trained to drink a fructose (8%)+saccharin (0.2%) solution mixed with one flavor (CS+/Fs) and a less-preferred 0.2% saccharin solution with mixed another flavor (CS-/s). Unlimited two-bottle tests with the two flavors in saccharin (0.2%: CS+/s, CS-/s) occurred 10 min following total bilateral NAcS doses of 0, 12, 24 or 48 nmol of SCH23390 or raclopride. Preference for CS+/s over CS-/s following vehicle treatment (76%) was significantly reduced by SCH23390 (48 nmol, 62%) and raclopride (24 nmol, 63%). In Experiment 2, rats received bilateral NAcS injections (12 nmol) of SCH23390 or raclopride on one-bottle training (16 ml) days. Yoked control rats received vehicle and were limited to the CS intakes of the D1 and D2 groups, whereas untreated controls without injections received their CS ration during training. Subsequent unlimited two-bottle tests revealed initial preferences of CS+/s over CS-/s in all groups that remained stable in untreated and yoked controls, but were lost over the six tests sessions in D1 and D2 groups. These data indicate that NAcS D1 and D2 antagonists significantly attenuated the expression of the fructose-CFP and did not block acquisition, but hastened extinction of fructose-CFP.
authors.affiliation: Neuropsychology Doctoral Subprogram, Graduate Center, City University of New York, New York, NY, USA.
authors.forename: Sonia Y
authors.initials: SY
authors.lastname: Bernal
authors.forename: Irina
authors.initials: I
authors.lastname: Dostova
authors.forename: Asher
authors.initials: A
authors.lastname: Kest
authors.forename: Yana
authors.initials: Y
authors.lastname: Abayev
authors.forename: Ester
authors.initials: E
authors.lastname: Kandova
authors.forename: Khalid
authors.initials: K
authors.lastname: Touzani
authors.forename: Anthony
authors.initials: A
authors.lastname: Sclafani
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Bodnar
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001552:Benzazepines / Q000494:pharmacology; D003214:Conditioning, Classical / Q000187:drug effects; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005518:Food Preferences / Q000187:drug effects / Q000502:physiology*; D005632:Fructose / Q000008:administration & dosage*; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D020891:Raclopride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D013549:Sweetening Agents / Q000008:administration & dosage*
chemical_list: D001552:Benzazepines; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013549:Sweetening Agents; D005632:Fructose; D020891:Raclopride